China
China AI solution provider Evomotion raises $20m
Evomotion, a China-based artificial-intelligence-of-things (AIoT) specialist that supplies software and chips to electronic appliance makers and supermarket retailers, has raised USD 20m in Series B funding.
Gaorong backs China energy storage company
China-based energy storage company WeView has raised CNY 400 million (USD 57m) from a group including Gaorong Capital, Green Pine Capital Partners, and ZhenFund.
China semiconductor player Shangda raises $99m
Chinese semiconductor packaging and testing company Shangda has raised a Series A extension of CNY700m (USD 99m) co-led by three government-backed funds.
Advent acquires China restaurant operator
Advent International has acquired a 60% stake in health food restaurant chain Wagas Group from its founders.
China semiconductor: Casualties of war
Private equity investment in China’s semiconductor industry continues unabated despite intensifying US regulatory action. While start-ups are not explicitly targeted, many are feeling the heat
China drug developer Worg secures $57m Series B
Worg, a China-based drug developer, has closed a Series B round of CNY400m (USD57m) from five local investors - Jiachen Capital, Longpan Capital, Kaitai Capital, Puhua Capital and Anji Ruixing Capital.
GenBridge, DragonBall back China snacks brand Xueji Chaohuo
GenBridge Capital and DragonBall Capital have led a CNY 600m (USD 86m) Series A round for Xueji Chaohuo, a China-based roasted seeds and nuts brand.
EQT exits China packaging business to OTPP
EQT has confirmed the sale of its co-control stake in China-headquartered packaging manufacturing company GPA Global to Ontario Teachers’ Pension Plan Board (OTPP) for an undisclosed sum.
China satellite player Galaxy Space achieves unicorn status
Galaxy Space, a China-based satellite developer, has raised a new funding round led by CCB International at a post-investment valuation of CNY 11bn (USD 1.6bn).
China's HighLight hits first close on life sciences fund, targets $650m
HighLight Capital, a China-based life sciences investor, has completed a first close of USD 540m on its fourth US dollar-denominated fund. The overall target is USD 650m.
China looks to boost PE participation by domestic insurers
Chinese Premier Li Keqiang has asked regulators to encourage investment by insurance companies in private equity and venture capital through measures such as shorter post-IPO lock-up periods.
L'Oréal China investment unit backs local fragrance brand
L'Oréal has completed the debut deal from its newly formed China investment arm by participating in an extended Series A round for local fragrance brand Documents.
Deal focus: L’Oréal shows staying power
Europe-based personal care giant L’Oréal looked past short-term impediments like lockdowns and asset price corrections to join Cathay Capital in supporting Chinese perfume brand Documents
TPG-backed Dingdang Health raises $51m in Hong Kong IPO
Chinese online pharmacy platform Dingdang Health has raised HKD 402.4m (USD 51m) through a Hong Kong IPO, defying challenging conditions for financial sponsors targeting the bourse.
China AI player Fourth Paradigm files for Hong Kong IPO
Fourth Paradigm, a China-based software provider that helps enterprise customers develop in-house artificial intelligence (AI) decision-making applications, has filed for a Hong Kong IPO.
China fitness app Keep pursues Hong Kong listing
Keep, a China-focused fitness app operator backed by the likes of GGV Capital, SoftBank Vision Fund 2, and 5Y Capital, has filed for a Hong Kong IPO.
China circuit board maker JLC raises $129m
Chinese circuit board manufacturing company Jialichuang (JLC) has raised CNY 900m (USD 129m) from State Development & Investment Corporation (SDIC), Eastern Bell Capital and Jianfa Xinxing Investment.
Deal focus: Turning data into operational efficiencies
Chinese data mining start-up Prothentic has managed to turn first-time business into repeat subscription business, which led to valuation increase between funding rounds even as the wider market stagnates
China drug developer BoomRay gets $43m
Chinese drug developer BoomRay Pharmaceuticals has raised a CNY300m (USD 43m) Series A round led by Sequoia Capital China.
China's Welkin Capital targets London IPO
China-focused Welkin Capital is looking to raise up to USD 300m through an IPO for a London-listed investment entity seeded with assets from its debut private equity fund, which closed in 2017.
China cell therapy developer Neukio raises $50m
Shanghai-based cell therapy developer Neukio Biotherapeutics has raised USD 50m in the first tranche of a Series A round led by medical technology-focused CD Capital. Other new investors include Alwin Capital and Surplus Capital.